Perspective Total Prescribing Details OPDIVO® (nivolumab) is indicated for that treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed right after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or following three or even more traces of systemic therapy that includes